These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 34901959

  • 1. The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
    Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K.
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [Abstract] [Full Text] [Related]

  • 2. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.
    Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
    Kitajima K, Maruyama M, Yokoyama H, Minami T, Yokoi T, Nakamura A, Hashimoto M, Kondo N, Kuribayashi K, Kijima T, Hasegawa S, Yamakado K.
    Cancers (Basel); 2021 Mar 04; 13(5):. PubMed ID: 33806464
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer.
    Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, Zhao W, Yang Z, Li N.
    Cancer Imaging; 2024 Sep 10; 24(1):120. PubMed ID: 39256860
    [Abstract] [Full Text] [Related]

  • 7. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S, Lee Y, Kim TS, Kim SK, Han JY.
    Medicine (Baltimore); 2020 Dec 18; 99(51):e23815. PubMed ID: 33371161
    [Abstract] [Full Text] [Related]

  • 8. Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy.
    Tricarico P, Chardin D, Martin N, Contu S, Hugonnet F, Otto J, Humbert O.
    J Immunother Cancer; 2024 Apr 22; 12(4):. PubMed ID: 38649279
    [Abstract] [Full Text] [Related]

  • 9. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 10. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Maruyama M, Minami T, Yokoi T, Kuribayashi K, Kijima T, Hashimoto M, Hasegawa S, Yamakado K.
    Nucl Med Commun; 2020 Aug 20; 41(8):790-799. PubMed ID: 32516245
    [Abstract] [Full Text] [Related]

  • 11. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
    Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP.
    J Nucl Med; 2019 Mar 20; 60(3):328-334. PubMed ID: 30030343
    [Abstract] [Full Text] [Related]

  • 12. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
    Kaira K, Yamaguchi O, Naruse I, Umeda Y, Honda T, Watanabe S, Ichikawa K, Yanagisawa S, Kasahara N, Higuchi T, Hashimoto K, Miura Y, Shiono A, Mouri A, Imai H, Iizuka K, Ishizuka T, Minato K, Suda S, Kagamu H, Mori K, Seki N, Kuji I.
    Cancer Imaging; 2023 Mar 01; 23(1):23. PubMed ID: 36859341
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.
    J Nucl Med; 2020 Jul 01; 61(7):990-998. PubMed ID: 31806768
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L.
    Clin Lung Cancer; 2021 Sep 01; 22(5):432-440. PubMed ID: 33879398
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.